Morphic Therapeutic Inc. has divulged integrin αvβ8 antagonists reported to be useful for the treatment of cancer.

Researchers at China Pharmaceutical University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have disclosed short transient receptor potential channel 5 (TRPC5) and/or short transient receptor potential channel 4 (TRPC4) ligands reported to be useful for the treatment of cancer and more.

Cascade Pharmaceuticals Inc. has disclosed new thyroid hormone receptor β (THRβ) agonists reported to be useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), hypothyroidism, atherosclerosis and dyslipidemia.

New miR-124 activators have been reported in a recent Nanjing Synnocare Pharmaceutical Technology Co. Ltd. patent as potentially useful for the treatment of Alzheimer type dementia, Parkinson’s disease, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, cancer and viral infections.

IRCCS San Raffaele, Universita Degli Studi Di Perugia and Universita Vita-Salute San Raffaele have jointly developed new oxysterols receptor LXR-α (NR1H3; LXRA) and/or LXR-β (NR1H2; LXRB) antagonists reported to be useful for the treatment of cancer, inflammatory and immunological disorders.

A Scandiedge Therapeutics AB patent details compounds targeting pyruvate kinase PKLR reported to be useful for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma.

The University of California and the US Department of Veterans Affairs have patented androgen receptor (AR) antagonists reported to be useful for the treatment of prostate cancer.

Norroy Bioscience Co. Ltd. has prepared drug conjugates comprising a radionuclide linked to a ligand targeting glutamate carboxypeptidase II (NAALADase; NAAG peptidase, FOLH1; PSMA) through a linker for use as positron-emission tomography (PET) imaging agents.

Novartis AG has reported new cyclin-dependent kinase 2 (CDK2) inhibitors potentially useful for the treatment of cancer.

Work at Dice Alpha Inc. has led to the discovery of new interleukin-17A (IL-17A) production inhibitors. They are reported to be potentially useful for the treatment of psoriasis, radiographic axial spondyloarthritis (ankylosing spondylitis), hidradenitis suppurativa, spondyloarthritis, psoriatic and rheumatoid arthritis.